Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

Researchers found that those with both type 2 diabetes and chronic obstructive pulmonary disease (COPD) had lower all-cause and respiratory-cause mortality survival probabilities than those without ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

We currently know that COPD, and specifically emphysema, is not just a lung disease found alongside lung cancer; it increases ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 agonists and co-agonists conferred better ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...